Butler Brings Strong Leadership, Vision and Experience to Company
GAITHERSBURG, Md. and YORK, England, Dec. 16 /PRNewswire/ -- Xceleron, the global leader in predictive clinical research to enable smarter, safer drug development, announced today Michael Butler, Ph.D., has been named President and CEO after an extensive global candidate search. Dr. Butler brings to Xceleron a balance of sales, operations and management know-how, including significant experience in expanding science-driven businesses.
"We are pleased to formally introduce Dr. Michael Butler and announce this key appointment. Not only will this move strengthen Xceleron's business operations, but the benefits derived across the organization from his leadership will be significant as the company drives revenue growth and expands its global footprint," said Dr. Ian Buckley-Golder, Chairman of the Board, Xceleron. "Michael's ability to deliver results, keen insight and deep understanding of science-driven businesses made him the ideal choice to lead Xceleron into the future."
Prior to joining Xceleron, Dr. Butler served as President and Chief Scientific Officer at Aptuit, a global pharmaceutical services company with more than 1,000 employees. Dr. Butler led Aptuit's growth phase working to penetrate key North American, European and Asian markets, increase sales revenues from $75 million to over $200 million, as well as expand operations from three locations to eight sites globally. Before Aptuit, Dr. Butler was Group Vice President at MDS Pharma Services responsible for managing the company's clinical and chemistry operational units.
"This is an exciting time to join Xceleron. Our customers are dealing with the most intractable challenges the industry has ever faced including poor compound solubility, biologics development, high potency drugs, and the need for earlier human data. With more than 200 molecules investigated to date, Xceleron has consistently demonstrated its ability to deliver the critical insights necessary to overcome each of these problems," said Dr. Butler. "Leveraging 11 years of experience, Xceleron offers the most robust analytical platforms in the industry and the technical know-how to solve our clients' drug development challenges. With the US facility online, we are ideally situated to bring this unique expertise to the largest market in the world."
Professor Colin Garner, founder of Xceleron is retiring from the President/CEO position and will now serve as the Senior Scientific Advisor to Xceleron and a non-Executive Director. "Over the past 11 years, Xceleron has created a new market to enable pharma and biotech companies to take drugs into humans earlier than ever before and at much lower cost," said Professor Garner. "I believe Michael is well suited to grow the Company as we continue to provide enhanced value to our customers and I look forward to supporting him in growing the business."
Dr. Butler received a BS with honors from Heriot Watt University and earned his Ph.D. from the University of Liverpool.
Leveraging proprietary methods and an ultra-sensitive analytical technology platform, Xceleron delivers the earliest possible, most relevant human insights to its clients enabling smarter and safer drug development decision-making. Xceleron maintains ongoing client engagements with 15 of the 20 largest pharmaceutical companies in the world and has investigated more than 200 molecules to date. The Company's data has been submitted in the packages of six approved drugs. For more information, log on to www.xceleron.com.
CONTACT: Alicia Moran, +1-410-991-7027, for Xceleron
Web site: http://www.xceleron.com/